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Abstract: Objective: Due to poor prognosis in advanced non-small cell lung cancer (NSCLC), new markers and more 
effective treatment methods are needed in the monitoring of the disease. The purpose of our study is to evaluate the 
clinical significance of serum vascular endothelial growth factor (VEGF) levels in patients with advanced NSCLC on 
prognosis and survival. 
Materials and method: Sixty seven patients (62 men and 5 women) and 20 healthy volunteers (16 men and 4 women) 
were included in our study. The demographic and laboratory data and serum VEGF levels of two groups were compared.  
Results: A statistically significantly high level of VEGF (p=0.0001) was detected in patients compared to the control 
group. The high level of serum VEGF has a statistically significant relationship with the short disease-free survival time 
(p=0.05). While the median progression free survival (PFS) time in patients with high VEGF levels was 157 days, the 
median PFS time in those with normal VEGF levels reached up to 340 days. This difference was statistically significant 
(p=0.003). When overall survival (OS) times was evaluated, it was 472 days in patients with low VEGF levels and 180 
days in those with high levels and the difference was statistically significant (p=0.001).  
Conclusion: In our study, the serum VEGF levels were determined to be statistically significant increased in the NSCLC 
patient group compared to the control group. In addition, a significant inverse relationship was discovered between the 
serum VEGF level and all survival times in the NSCLC patient group.  
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INTRODUCTION 
Lung cancer constitutes an important health 
problem throughout the whole world due to its ever-
increasing incidence and mortality rate. Lung cancer 
comes in the lead among deaths associated with 
cancer in both genders. Even though significant 
developments have been achieved over the recent 
years in multimodal therapies, 5-year survival could 
only reach 15%. This situation has directed 
researchers towards studies aiming to develop efficient 
and targeted therapies by revealing and in accordance 
with the genetic, molecular, and biological 
characteristics of the disease [1]. 
Today, targeted therapies have started to be used 
gradually more frequently in the field of cancer 
treatment. Potential targets have focused on tumor 
angiogenesis and proliferation, because angiogenesis 
is an essential basic mechanism for tumor proliferation. 
Tumor cells increase the secretion of growth factors 
that are required for the differentiation and migration of 
endothelial cells that constitute the building blocks of 
the vein. The vascular endothelial growth factor 
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(VEGF) is the most efficient growth factor for 
endothelial cells [2]. 
Development of high angiogenic activity associated 
with excessive VEGF excretion at a rate of 30% - 40% 
is reported in non-small cell lung cancer (NSCLC) 
patients. Many studies have shown that the existence 
of angiogenesis and micro vessel density constituted 
negative prognostic factors for survival [3, 4]. 
Due to poor prognosis in advanced (NSCLC) 
patients, new markers and more effective treatment 
methods are needed in the monitoring of the disease. 
Serum VEGF is the most potent angiogenetic factor 
defined today. The purpose of our study is to evaluate 
the impacts of serum VEGF levels in advanced NSCLC 
patients in diagnosis and prognosis. 
MATERIAL AND METHOD 
1. Patients and Control Group 
With the approval of the Medical Ethics Committee 
of the Medical Faculty of Pamukkale University, 67 
patients, who were examined by the Medical Oncology 
Department of our hospital for the first time, who had 
not previously received chemotherapy, and who were 
pathologically diagnosed with NSCLC, were evaluated 
in our study. Patients at advanced stage (stage IIIB and 
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stage IV) with a performance of 0, 1, and 2 according 
to the World Health Organization (WHO) classification 
were included. Voluntariness was taken as basis for 
participation in the study. Those with a performance of 
3 or worse at the time of application, with brain 
metastasis or suspected brain metastasis, aged 80 or 
over, with early stage (I, II, and IIIA) disease, and who 
did not sign the informed consent form were not 
included in the study.  
A control group was formed from 20 healthy 
subjects between the ages of 53-79 (average 63.1± 
6.3), who did not use any medicine and who did not 
have any known chronic disease. Attention was paid to 
ensure that the individuals constituting the control 
group were comparable with the patient group in terms 
of age and gender. 16 persons within the healthy 
control group were men (80%) and 4 of them were 
women (20%).  
The age and gender of the patients and the control 
group, the tumor types, treatments, and pre-treatment 
performances of patients were recorded. An 
informative meeting was organized to explain the 
purpose and scope of the study to the individuals 
constituting the control and patient groups and written 
informed consent forms were received from the 
individuals.  
2. Biochemical Analysis 
Venous blood samples obtained for VEGF from the 
patient and control group on an empty stomach in the 
morning following a night time fasting were taken in 
vacuum tubes, centrifuged for 10 minutes at 15,000 
rpm to separate the serum portion, and preserved in 
deep-freezer at -700 C. VEGF was measured with the 
ELISA (Enzyme-Linked Immunosorbent Assay) method 
(Digital and analog system, DAS, Palombara Sabina 
Italy).  
The VEGF cut-off value was calculated with the 
automatic program included in the packaged software 
named Statistical Package for Social Sciences version 
15.0 (SPSS-15.0, for windows). The cut-off value for 
VEGF was found to be 934 ng/ml. Those equal to or 
lower than these values were considered as low and 
those above were evaluated as high. Different cut-off 
values are included in NSCLC studies evaluating the 
VEGF level with the ELISA method in literature, and 
500 pg/ml, 630 pg/ml, 500 pg/ml, and 119 pg/ml values 
were selected as cut-off in four different studies, by 
which the existence of a significant relationship 
between prognosis and VEGF was shown,  
respectively [4].  
3. Statistical Analysis 
The statistical analysis was conducted with the 
SPSS-15.0, for windows packaged software. The 
results were evaluated within the confidence interval of 
95%. P<0.05 was accepted as statistically significant. 
The chi-square and the Mann Whitney-U tests were 
applied in the comparison of the characteristics of the 
control group and the patients. The Spearman and 
Pearson correlation test was applied for correlation 
analyses. The Kaplan Meier method was used for OS 
and PFS times and time-survival curves. Logistic 
regression analysis was applied for the analyses of the 
factors that affected survival and progression. 
RESULTS 
The main clinical and demographic characteristics 
of patient and control groups have been shown in 
Table 1. 
Table 1: Demographic and Clinical Characteristics of 
Patient and Control Groups 
Characteristics Patient Group (n=67) (%) 
Control Group 
(n=20) (%) 
Age (years) 62.9 ± 8.7 63.1±6.3 
Gender (female/male) 5 (7.5) / 62 (92.5) 4 (20) / 16 (80) 
Performance state 0-1  58 (86.6) 20 (100) 
2 9 (13.4) 0 
Additional disease (yes) 24 (35.8) 0 
Smoking (yes) 54 (80.6) 0 
 
The serum VEGF levels in patient and control 
groups have been shown in Table 2.  
Table 2: Serum VEGF Distributions of Patient and 
Control Groups 
 Patient (n=67) Control (n=20) p Value 
VEGF (ng/ml) 1089.7 ± 509  508.6±451.8 0.0001* 
*p < 0.05 was considered to be significant. 
The patients were divided into two groups as the 
group with high VEGF level (above 934 ng/ml) and the 
group with low VEGF levels (934 ng/ml and lower), and 
evaluated according to their clinical and pathological 
characteristics in Table 3.  
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Table 3: Relationship of Serum VEGF Levels and 
Clinical Characteristics in the Patient Group 
Clinicopathological 
Characteristics VEGF Low VEGF High P Value 
Histology (n=67)                                                                      0.757  
Squamous 17 27  
Non-squamous 8 15  
Histology (n=67)                                                                      0.772  
Adenocarcinoma 5 10  
Non-adenocarcinoma  20 32  
Progression (n=67)                                                                 0.085  
No 8 6  
Yes 17 36  
Final state of the patient (n=67)                                             0.006*  
Alive 11 5  
Exitus 14 37  
Age (n=67)                                                                              0.085  
Below 55 years  8 6  
55 years and older 17 36  
Existence of metastasis (n=67)                                               0.068  
Yes  5 18  
No 20 24  
Albumin (n=67)                                                                       0.077  
Above 3 g/dl  25 36  
3 g/dl and lower 0 6  
Performance state (n=67)                                                       0.466  
0-1 23 35  
2-4 2 7  
 
While the median PFS time in patients with high 
VEGF levels was 157 days, the median PFS time in 
those with normal VEGF levels reached up to 340 
days. This difference was statistically significant 
(p=0.003) (Figure 1). 
When the median OS times was evaluated, this was 
found to be 472 days in patients with low VEGF levels 
and 180 days in those with high VEGF levels and the 
difference in between was statistically significant 
(p=0.001) (Figure 2). 
 
Figure 2: Overall survival curve according to VEGF level. 
When evaluated with multivariate analysis, the high 
levels of VEGF was shown to have significantly 
affected all OS (8.8 times, p=0.003). 
DISCUSSION 
VEGF levels, which are known to play an important 
role in angiogenesis, were found to be high in NSCLC 
patients compared to healthy control groups [5, 6]. Taş 
et al. [5] compared the serum VEGF levels of 52 
NSCLC patients and 16 healthy persons in a control 
group and found the VEGF level to be higher in the 
patient group. In another study, a statistically significant 
difference was found between the serum VEGF levels 
of 21 advanced NSCLC patients and those of 46 
healthy volunteers [6]. We also found the serum VEGF 
levels to be statistically significantly high in the NSCLC 
patient group compared to our control group 
(p=0.0001), which was consistent with the literature. 
Since the evaluations of the circulatory quantity of 
angiogenic factors have certain advantages over IHC 
(immunohistochemical) evaluation, we examined the 
 
Figure 1: Progression free survival curve according to VEGF 
level. 
10    World Journal of Oncology Research, 2017, Vol. 4 Degirmencioglu et al. 
relationship between the serum VEGF value and 
survival and prognosis. These advantages are that it is 
more economic, easier, less time consuming, and 
easily repeatable, it does not require a tumor tissue, it 
is suitable for preoperative examination, and involves 
lower possibility of partiality. Delmotte et al. [7] 
examined the serum VEGF values in a total of 1549 
NSCLC patients in 15 studies in their meta analyses 
and reported that micro vessels density and VEGF 
expression constituted a poor prognostic factor for 
survival at a statistically significant level (HR 1.8-2.0 
and HR 1.5, respectively). Kim et al. [8] showed a 
statistically significant relationship between high serum 
VEGF levels and short OS time in 140 advanced stage 
NSCLC patients in their study. We also determined a 
significant relationship between serum VEGF levels 
and NSCLC prognosis and survival, which was 
consistent with the literature. 
Fontanini et al. [9] immunohistochemically evalua- 
ted VEGF expression and density and number of micro 
vessels in tissue samples surgically resected from 105 
NSCLC patients in their study. A statistically significant 
relationship was reported between the excessive 
excretion of VEGF and lymph node involvement, 
between the micro vessel density, and between 
survival and the period until progression. Yuan et al. 
[10] evaluated a total of 72 resected stage I, II, and III a 
NSCLC patients in their study. 4 VEGF mRNA isoforms 
were measured and micro vessel density was 
examined with the reverse transcriptase (RT) PCR 
method. As a result, they concluded that the patients 
with high VEGF mRNA expression were at a more 
advance stage and they had more lymph node 
involvement, higher micro vessel density in their tumor 
tissues, shorter survival times, and faster relapse rates. 
In the study conducted by Song et al. [11] serum VEGF 
levels in 48 newly diagnosed NSCLC patients were 
found to be significantly higher compared to those of 
the control group and furthermore, the serum VEGF 
levels increased with the increase in stages in NSCLC 
patients. Bieniasz et al. [12] showed in their study that 
serum VEGF levels also increased in a statistically 
significant manner with the increase of T stage 
according to the TNM system in NSCLC cases. It was 
found in the study conducted by Zhang et al. [13] that 
serum VEGF levels were significantly higher in the 
existence of lymph node involvement, which 
constituted an important part of staging, compared to 
node negative patients. In our study as well, results 
close to a statistically significant difference were found 
between the prevalence of the disease and the 
increase in the serum VEGF level as consistent with 
the literature (p=0.068). The low number of our patients 
may constitute a factor in the non-significance of the 
difference.  
Imaging methods used for evaluation after cytotoxic 
therapies can only examine macroscopic changes after 
receiving at least 2 to 3 cycles of chemotherapy, in 
other words, after a long period of time passes. In 
addition, these methods involve radiation effects that 
are harmful to the patient. Therefore, the need for a 
simpler and more practical method that would evaluate 
the efficiency of the treatment at an earlier stage and 
show the contribution of the treatment on the response 
is ever increasing. For this reason, it is possible for 
tumor markers to evaluate a series of changes. Even 
though CEA, CYFRA 21-1, and nucleosomes are 
beneficial in predicting the diagnosis for NSCLC, they 
have not yet entered in clinical practice [14]. Changes 
in serum VEGF levels can also be used for the purpose 
of evaluating the treatment response. In a study 
performed with this aim, serum VEGF levels were 
examined 3 times in 42 newly diagnosed advanced 
NSCLC patients before platinum-based chemotherapy 
and before the second and third cycles of 
chemotherapy. VEGF dropped by a statistically 
significant rate compared to the basal level in patients 
in remission following the first cycle of chemotherapy. 
The VEGF level changes compared to the basal level 
prior to the second cycle displayed 71.4% sensitivity 
and 71.4% specify in the early prediction of the 
progression of the disease. However, as different from 
our study, a relationship was not found between the 
basal serum VEGF levels and survival in this  
study [14].  
CONCLUSION 
The prognostic role of VEGF for advanced NSCLC 
was shown in our study. VEGF can be used as a 
potential marker in NSCLC diagnosis. The aggressivity 
of treatment may be decided based on the serum 
VEGF levels. Likewise, it is possible to benefit from 
serum VEGF levels in evaluating response following 
treatment. However, many studies including more 
patients are needed in order to reveal the potential 
value of VEGF levels in NSCLC diagnosis and 
prognosis. 
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